The neutralization of TGF-β has been looked at as a cancer therapy for preventing tumor-sensitized Tregs [16,17,21], augmenting anti-tumor responses [22] and inhibiting metastases [15,23]. The gene discussed is TGFB1; the disease is neoplasm.